JMP maintains $5 price target on Clearside Biomedical stock

Published 23/04/2025, 10:10
JMP maintains $5 price target on Clearside Biomedical stock

On Wednesday, JMP Securities analyst Jonathan Wolleben reaffirmed a Market Outperform rating on Clearside Biomedical (NASDAQ:CLSD) stock, with a steady price target of $5.00. The micro-cap biotech company, currently trading at $0.80 with a market capitalization of $61.5 million, has seen analyst targets ranging from $4.00 to $8.00, according to InvestingPro data. Wolleben’s outlook is tied to the company’s upcoming pivotal trials for its wet Age-Related Macular Degeneration (AMD (NASDAQ:AMD)) treatment, CLS-AX, set to commence in the second half of 2025.

Clearside Biomedical is gearing up for significant clinical trials, which will test CLS-AX against the current standard treatment, Eylea. These trials are designed to be non-inferiority studies with flexible dosing regimens, a strategy that mirrors successful programs for other treatments like Vabysmo and Eylea HD. Despite showing impressive gross profit margins of 91%, InvestingPro analysis indicates the company is rapidly burning through cash, with comprehensive research reports available for deeper insights into the company’s financial health.

The analyst pointed out that CLS-AX’s design allows for earlier re-dosing intervals, setting it apart from other Tyrosine Kinase Inhibitor (TKI) programs. This feature could lend the drug a more adaptable label, providing physicians with the ability to tailor treatments to individual needs while also potentially extending the time between treatments.

Wolleben also noted that while the Phase 2 results of CLS-AX were competitive, there is potential for improved durability in Phase 3. He attributes this to the possibility of enrolling patients who are easier to treat, such as those who have not previously received treatment for wet AMD, compared to the Phase 2 trials that included patients with active disease.

The trial’s design will be stricter in terms of inclusion and exclusion criteria, aiming to reduce variability among patients. This could contribute to more consistent and reliable trial outcomes, as the company seeks to demonstrate the efficacy and safety of CLS-AX for wet AMD treatment. With a beta of 2.04 and a strong current ratio of 4.44, the company maintains adequate liquidity for its operations, though investors should note the stock’s significant volatility. Clearside Biomedical’s stock price target remains unchanged at $5.00, as the company approaches a critical phase in its development program.

In other recent news, Clearside Biomedical reported its fourth-quarter 2024 earnings, revealing a significant revenue beat with $306,000 compared to the forecasted $130,140. The company’s earnings per share (EPS) matched expectations at -0.1. Stifel analysts maintained a "Buy" rating and set a price target of $8.00, noting the company’s rapid progress toward Phase 3 trials for its drug CLS-AX, designed for wet age-related macular degeneration (wAMD). JMP Securities also reiterated a Market Outperform rating with a $5.00 price target, highlighting the upcoming pivotal trials for CLS-AX, which aim to demonstrate its flexible dosing regimen. Clearside Biomedical’s partnered portfolio is advancing, with Arctic Vision receiving approvals for Arcatus in Australia and Singapore, and a collaboration with ABBV/RGNX leading to the progression of ABBV-RGX-314 into Phase 3 trials for diabetic retinopathy in 2025. The company ended 2024 with $20 million in cash, expected to fund operations into late 2025, while actively seeking additional capital for its Phase 3 trials. Analysts emphasized the strategic steps Clearside Biomedical is taking to advance its CLS-AX treatment through the pivotal stages of clinical development.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.